The MEK/ERK1/2 pathway is a key mediator of cellular proliferative, migratory, and invasive activity that is commonly activated in oncogenic settings including gallbladder cancer, breast cancer, and HNSCC 26-28. Here, MAPK3 is linked to head and neck squamous cell carcinoma.